Recordati SpA is shelling out $825 million up front for global rights to Enjaymo (sutimlimab), the only therapy approved for treating the rare disease cold agglutinin disease. In the deal with Sanofi ...

Under the deal announced Friday, the Italian pharma will make an upfront payment of $825 million to Sanofi for global rights ...

JNJ files for voluntary bankruptcy for the third time. Pfizer withdraws sickle-cell drug drug Oxbryta from worldwide markets.

The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to ... Studies for additional therapeutic ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

Eli Lilly has received approval in Japan for Kisunla (donanemab-azbt) to treat early symptomatic Alzheimer's disease.

Fulcrum has long believed blocking an enzyme involved in the production of DUX4 with losmapimod — a drug GSK discovered and originally developed for a heart condition — would improve outcomes. Now, ...

As a Therapist, Here Are 5 Habits That Could Be Making Your Anxiety Way Worse South Dakota governor seeks audits of tribes Alzheimer's Slowed by Intensive Lifestyle Changes ...

For their defenders, the drugs lecanemab and donanemab represent ... breakthrough new drug, Durand told AFP. He also feared that laboratories could lose interest in Alzheimer's disease due to ...